Attached files
file | filename |
---|---|
EX-32.2 - EX-32.2 - Foghorn Therapeutics Inc. | d105868dex322.htm |
EX-31.2 - EX-31.2 - Foghorn Therapeutics Inc. | d105868dex312.htm |
EX-31.1 - EX-31.1 - Foghorn Therapeutics Inc. | d105868dex311.htm |
EX-23.1 - EX-23.1 - Foghorn Therapeutics Inc. | d105868dex231.htm |
EX-10.18 - EX-10.18 - Foghorn Therapeutics Inc. | d105868dex1018.htm |
EX-4.6 - EX-4.6 - Foghorn Therapeutics Inc. | d105868dex46.htm |
10-K - 10-K - Foghorn Therapeutics Inc. | d105868d10k.htm |
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of Foghorn Therapeutics Inc. (the Company) on Form 10-K for the year ended December 31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the Report), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
(1) | The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
(2) | The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company. |
Date: March 18, 2021
/s/ Adrian Gottschalk |
Adrian Gottschalk
President, Chief Executive Officer and Director
(Principal Executive Officer)